AzTrials
AzTrials

Comparison of Efficacy of Sclerotherapy in Infantile HemangiomahemangiomaNCT06080724

Efficacy of Intralesional Bleomycin Alone and in Combination With Dexamethasone in Infantile Haemangiomas

A study testing Comparison of intralesional injection of bleomycin alone and combined with injection dexamethasone in people with Comparison of Efficacy of Sclerotherapy in Infantile Hemangioma, run by King Edward Medical University at 1 site in Pakistan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Objective: This study is intended to compare the outcome of intralesional bleomycin with dexamethasone versus the bleomycin alone in infantile haemangioma. Materials and Methods: This RCT was performed after the ethical approval at the pediatric surgery department of KEMU/Mayo hospital Lahore. Read more about this study

Who is it for?
Ages 1 month to 12 years
What is being tested?
Comparison of intralesional injection of bleomycin alone and combined with injection dexamethasone
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
114 participants
Where
1 sitePakistan
Study dates
22 Mar 2021to 20 Mar 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 month to 12 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Patients with haemangioma with size equal or more than 1 c
  • Less than 12 years and above 1 month of age.

Who cannot join

  • Patients with previous surgical procedure for haemangiomas
  • Patients with chronic respiratory conditions confirmed by history, symptoms and physical examination.
  • The diagnosed case of pulmonary fibrosis.
  • Patients sensitive to bleomycin proved upon giving a test dose

Trial locations and contacts

1 site in 1 country.

Pakistan1 site
  • department of pediatric surgery King Edward Medical University

    Lahore, Punjab Province, 54000

Other trials in Pakistan

About this study

Objective:

This study is intended to compare the outcome of intralesional bleomycin with dexamethasone versus the bleomycin alone in infantile haemangioma.

Materials and Methods:

This RCT was performed after the ethical approval at the pediatric surgery department of KEMU/Mayo hospital Lahore. 114 patients were enrolled in two groups A and B. Both groups contained 57 patients each. Group A was administered intralesional bleomycin with dexamethasone and group B was given intralesional bleomycin alone with a space of 4 weeks. Selection of patients was made according to inclusions and exclusion criteria.

Read the detailed description

Introduction:

Infantile haemangioma (IH) is a common tumor found in children. The history of this tumor consists of an early phase of growth followed by slow resolution over a period of three to seven years but can extend up to 12 years. Therapeutic intervention is usually not required in infantile hemangiomas due to spontaneous regression. In about 10 to 15% of cases IH located in the perineal, airway or periocular areas, or hemangiomas associated with complications of ulceration, intervention is necessary. Another reason for intervention in these hemangiomas is the probability of scar formation with complete or incomplete spontaneous involution. Currently available treatment options for IH range from topical, intralesional, systemic and laser therapies to surgery based on the stage and presentation of the tumor. The choice of treatment must be carefully selected after comparing the merits and risks of each modality through a patient-specific approach.

OPERATIONAL DEFINITION:

Infantile Haemangioma: is a benign vascular proliferative disorder which has an early period of proliferation and then regresses spontaneously. They are found during the infancy and are considered medically benign lesions.

Efficacy: The desired effect obtained after giving a treatment is termed as efficacy. Efficacy of the treatment was measured in terms of reduction of the size of haemangioma which in turn was assessed by measuring length, width, height and volume every month to a period of one year. The decrease in size was graded on 5 point scale where 1= < 50% reduction, 2= 50-75%, 3= 75-90%, 4= >90% but < 100% and 5= 100%[17]. The complete flattening of haemangioma was considered as resolution of the lesion and at least the reduction in size of grade 2 results was labelled as the treatment being efficacious.

Intralesional Injection: After aseptic measures the injection was administered using a 26 gauge needle by directly injecting into the haemangioma in 4 different directions (the lesion was divided into 4 imaginary quadrants by drawing to perpendicular lines) through the single puncture point. Sterile gauze was used for pressure until the bleeding stopped.

Dosage: The intralesional dose of bleomycin was 1 mg/kg/dose but for haemangiomas on neck and face it was used as 0.5 mg/kg/dose and similarly intralesional dexamethasone was given as 0.8-1.6 mg/kg/dose. Both the drugs were administered intralesionally every 4 weeks. Every patient was checked for sensitivity to the drugs.

Treatment Response: The response of the treatment was evaluated by measuring Length, Width, Height and Volume. The length, width and height was measured using a vernier calliper in centimeters before administering the first injection and then after every 4 weeks following each injection.

Hypothesis:

The intralesional bleomycin combined with dexamethasone is more efficacious than intralesional bleomycin alone in infantile haemangioma.

Material and Methods:

Study Design: It was be a Randomized Controlled Trial.

Study Setting: The study was conducted in Pediatric surgery department, KEMU/Mayo Hospital Lahore.

Duration Of The Study: 1 year after the approval of the synopsis. Sampling Technique: Probability simple random sampling. Sample Size: Sample size of 114 patients ( 57 patients in each group ) is estimated by using 95% confidence level, 10% absolute precision with expected percentage of intralesional bleomycin combined with dexamethasone as 100%[15] and intralesional bleomycin alone as 82%[10] .

n = Z1-α/2 [ P1 (1- P1) + P2 (1- P2) ] d2 Where n = sample size P1 = population proportion I = 100% P2 = population proportion II = 82% Z1-α/2 = confidence level 95% = 1.96 d = absolute precision 10%

Sample Selection:

Inclusion Criteria:

  1. Patients with haemangiomas presenting to pediatric surgery department KEMU/Mayo hospital Lahore with size equal or more than 1 cm.
  2. Patients </= 12 years and above 1 month of age.

Exclusion Criteria:

  1. Patients who had undergone any surgical procedure for haemangiomas proved from the history.
  2. Patients with chronic respiratory conditions confirmed by history, symptoms and physical examination.
  3. The diagnosed case of pulmonary fibrosis.
  4. Patients sensitive to bleomycin proved upon giving a test dose.

DATA COLLECTION PROCEDURE:

Permission was taken from the ethical review board. Patients were selected as per inclusion and exclusion criteria. Written informed consent was taken from parents/guardians regarding inclusion in study and sharing of data after counseling about the procedure, drug effects and follow up. A randomized control trial study was conducted on patients of haemangiomas of pediatric age group coming to pediatric surgery ward, KEMU/Mayo hospital, Lahore. Patients were randomized in two study groups A and B. The Lottery method was used for allocation of patients where the patient was given allocated treatment regimen after opening the sealed envelope. Each group contained 57 of patients. Patients in the group A were given intralesional bleomycin combined with dexamethasone and in the group B intralesional bleomycin alone after taking aseptic and antiseptic measures. The intralesional dose of bleomycin was 1 mg/kg/dose but for haemangiomas on neck and face it was used as 0.5 mg/kg/dose and similarly intralesional dexamethasone was given as 0.8-1.6 mg/kg/dose. The Length, Width, Height and volume of haemangioma was measured in centimeters using a vernier calliper. The decrease in size was graded from 1-5 where 1=<50% decrease, 2=50-75%, 3=75-90%, 4=>90% but <100% and 5= 100% resolution. The data collection sheet included patent's age, sex, length, width, height, volume, site of haemangioma, dose of bleomycin, dexamethasone, clinical response being efficacious or non-efficacious as per operational definition and time taken to resolve for each patient.

DATA ANALYSIS PROCEDURE:

Data was entered and processed by using SPSS-26. Quantitative variable like age, length, width, height, volume, grades of improvement and time for resolution was presented as mean+SD . Qualitative variables like site of haemangioma, gender and efficacy was described using frequencies and percentages. Comparison of two groups "intralesional bleomycin alone" and "intralesional bleomycin combined with dexamethasone" was done by applying independent sample t-test. P-value if <0.05 was taken as significant.

Being tested
Comparison of intralesional injection of bleomycin alone and combined with injection dexamethasone
Keywords
infantile hemangioma, Bleomycin, Sclerotherapy, Dexamethasone, Combined sclerotherapy
Medical subject headings
Hemangioma, Capillary

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Comparison of intralesional injection of bleomycin alone and combined with injection dexamethasoneDrug

    already described

Study groups in NCT06080724
Study groupRoleWhat they receive
Group A with intralesional injection of bleomycin with dexamethasoneOtherPatients in the group A(n=57) were given intralesional bleomycin combined with dexamethasone and The intralesional dose of bleomycin was 1 mg/kg/dose but for haemangiomas on neck and face it was used as 0.5 mg/kg/dose and similarly intralesional dexamethasone was given as 0.8-1.6 mg/kg/dose. The Length, Width, Height and volume of haemangioma was measured in centimeters using a vernier calliper. The decrease in size was graded from 1-5 where 1=<50% decrease, 2=50-75%, 3=75-90%, 4=>90% but <100% and 5= 100% resolution. The data collection sheet included patent's age, sex, length, width, height, volume, site of haemangioma, dose of bleomycin, dexamethasone, clinical response being efficacious or non-efficacious as per operational definition and time taken to resolve for each patient.
Receives: Drug: Comparison of intralesional injection of bleomycin alone and combined with injection dexamethasone
Group B WITH INTRALESIONAL INJECTION OF BLEOMYCINOtherPatients in the group B(n=57) intralesional bleomycin alone after taking aseptic and antiseptic measuresThe intralesional dose of bleomycin was 1 mg/kg/dose but for haemangiomas on neck and face it was used as 0.5 mg/kg/dose.The Length, Width, Height and volume of haemangioma was measured in centimeters using a vernier calliper. The decrease in size was graded from 1-5 where 1=<50% decrease, 2=50-75%, 3=75-90%, 4=>90% but <100% and 5= 100% resolution. The data collection sheet included patent's age, sex, length, width, height, volume, site of haemangioma, dose of bleomycin, dexamethasone, clinical response being efficacious or non-efficacious as per operational definition and time taken to resolve for each patient.
Receives: Drug: Comparison of intralesional injection of bleomycin alone and combined with injection dexamethasone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Decrease in size of lesion

    The Length, Width, Height and volume of haemangioma was measured in centimeters using a vernier calliper. The decrease in size was graded from 1-5 where 1=<50% decrease, 2=50-75%, 3=75-90%, 4=>90% but <100% and 5= 100% resolution.

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Oct 2023
  2. Study start22 Mar 2021
  3. Primary completion2 Dec 2021
  4. Study completion20 Mar 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
A randomized control trial study was conducted on patients of haemangiomas of pediatric age group coming to pediatric surgery ward, KEMU/Mayo hospital, Lahore. Patients were randomized in two study groups A and B. The Lottery method was used for allocation of patients where the patient was given allocated treatment regimen after opening the sealed envelope. Each group contained 57 of patients. Patients in the group A were given intralesional bleomycin combined with dexamethasone and in the group B intralesional bleomycin alone after taking aseptic and antiseptic measures. T
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
114 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06080724
Sponsor's protocol ID
0000
Acronym
hemangioma
Status last verified
Oct 2023
First submitted
9 Sep 2023
Last updated
12 Oct 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Comparison of intralesional injection of bleomycin alone and combined with injection dexamethasone in people with Comparison of Efficacy of Sclerotherapy in Infantile Hemangioma, run by King Edward Medical University at 1 site in Pakistan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Decrease in size of lesion (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Oct 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in